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The objective was to use carbon nanotubes (CNT) coupled with near-infrared radiation
(NIR) to induce hyperthermia as a novel non-ionizing radiation treatment for primary brain
tumors, glioblastoma multiforme (GBM). In this study, we report the therapeutic potential
of hyperthermia-induced thermal ablation using the sequential administration of carbon
nanotubes (CNT) and NIR. In vitro studies were performed using glioma tumor cell lines
(U251, U87, LN229, T98G). Glioma cells were incubated with CNTs for 24 h followed by
exposure to NIR for 10 min. Glioma cells preferentially internalized CNTs, which upon NIR
exposure, generated heat, causing necrotic cell death. There were minimal effects to nor-
mal cells, which correlate to their minimal uptake of CNTs. Furthermore, this protocol
caused cell death to glioma cancer stem cells, and drug-resistant as well as drug-sensitive
glioma cells.This sequential hyperthermia therapy was effective in vivo in the rodent tumor
model resulting in tumor shrinkage and no recurrence after only one treatment. In conclu-
sion, this sequence of selective CNT administration followed by NIR activation provides a
new approach to the treatment of glioma, particularly drug-resistant gliomas.
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INTRODUCTION
Glioblastoma multiforme (GBM), World Health Organization
(WHO) grade IV, is the most aggressive type of primary brain
tumor (1). Median survival is only 12–15 months and 5-year sur-
vival is <5% regardless of treatment. Standard of care consists of
surgery, followed by radiation and chemotherapy, usually temo-
zolomide (TMZ). These therapies have significant side effects and
routinely result in the recurrence of drug-resistant tumors (2, 3).
Unfortunately, upon recurrence, patients have very limited treat-
ment options. Chemotherapy with bevacizumab is often used as
second line therapy (4). Further, ionizing radiation is generally
not recommended, although radiosurgery boost has been used in
some selected situations (5). Photothermal treatment is an alter-
native therapy, which induces cytotoxicity to drug-sensitive and
-resistant tumor cells (6). This therapy involves the induction of
hyperthermia, defined as temperatures above 40°C. This thera-
peutic intervention causes irreparable cell damage to tumor cells,
while causing some damage to normal cells (7, 8). The main prob-
lem with hyperthermia is the difficulty in specifically targeting cell
populations for destruction. Our approach to specificity is the use
of carbon nanotubes (CNT) to regulate the levels of hyperthermia.
CNTs possess particular electrical, optical, and thermal properties
generated by the arrangement of the carbon atoms in a three-
dimensional cylindrical nanostructure (9). These structures have
strong optical absorptions in the near-infrared radiation (NIR)
range (700–1400 nm) and generate heat through the release of
vibrational energy. This property can be utilized for the induction
of hyperthermia (10). Photothermal therapy for cancer has been a
topic of recent investigation because this treatment strategy results
in few side effects, limited invasiveness, and enhanced sensitivity
of tumor cells to hyperthermia (8, 11). Wavelengths in the NIR
range have a great advantage for in vivo applications because they
cover the tissue-transparency window of the light spectrum (12).
Furthermore, the low absorbance of NIR by water and biological
tissues provides a favorable platform to irradiate CNTs. Hence, the
combination of CNTs and NIR appears to be a promising therapy
for glioblastoma treatment.
In this study, we demonstrate that the combination of CNTs and
NIR is an effective photothermal therapy that selectively affects
both drug-sensitive and -resistant glioma cells and tumor initiat-
ing glioma cancer stem cells (GSC), while sparing normal cells.
Furthermore, these studies demonstrate that this therapy is effec-
tive in vivo for drug-resistant tumors without significant pathology
to neighboring normal control tissues.
MATERIALS AND METHODS
CELL CULTURE AND TREATMENTS
U251 TMZ-sensitive cells, U251 TMZ-resistant, U87 glioma cells,
U87 TMZ-resistant, LN229 glioma cells, LN229 TMZ-resistant,
and T98G glioma cells were cultured in 10% fetal calf serum
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(FCS; Omega Scientific Inc., Tarzana, CA, USA) in Dulbecco’s
Modified Eagle’s Media (Corning, Santa Clara, CA, USA) supple-
mented with 100 U/mL penicillin and 0.1 mg/mL streptomycin.
Human brain endothelial cells (BEC) and astrocytes were cultured
in RPMI 1640 growth media (Mediatech Inc., Manassas, VA, USA)
supplemented with 100 ng/mL EC growth supplement (Millipore,
Temecula, CA, USA), 10 mmol/LN -2-hydroxyethylpiperazine-N -
2-ethanesulfonic acid (HEPES) (Invitrogen, Carlsbad, CA, USA),
24 mmol/L sodium pyruvate (Invitrogen), 300 U heparin (Sigma-
Aldrich, St. Louis, MI, USA), 1× minimum essential medium
(MEM) vitamin solution (Invitrogen), 1× MEM non-essential
amino acids (Mediatech Inc.), 1% penicillin/streptomycin (Invit-
rogen), and 10% FCS. Cancer stem cells were cultured in serum-
free medium composed of Dulbecco’s modified Eagle medium
[(DMEM)/F12+GlutaMAX-I)] supplemented with 100 U/mL
penicillin, 0.1 mg/mL streptomycin, 1% B27 supplement (Invit-
rogen), 20 ng/mL epidermal growth factor (EGF; PeproTech, Oak
Park, CA, USA), and 20 ng/mL basic fibroblast growth factor-2
(FGF)-2 (Peprotech). Glioma cell lines were originally purchased
from ATCC; TMZ-resistant cells were developed by serial passag-
ing of tumor cells with increasing concentrations of TMZ. CNTs
were purchased from Nanointegris (Nanointegris, Menlo Park,
CA, USA). For cell treatments, cells were kept in culture in the
presence of CNTs for 24 h prior to NIR exposure.
FLUORESCEIN-LABELING OF CNTs
Carbon nanotubes (Sigma-Aldrich) were shortened and
carboxylated by heating in acid to yield highly func-
tionalized nanotubes. Oxidized CNTs were reacted with
fluorescein-5-thiosemicarbazide (FC) (1 mg/ml) and 1-ethyl-3-
(3-dimethylaminopropyl)-carbodiimide (EDC) for 2 h at room
temperature (RT). The mixture was filtered with a molecular
weight cut-off of 100,000. The residue was washed with PBS sev-
eral times and then collected and dispersed in PBS by sonication
to make a suspension of CNT–FC of 0.25 mg/ml.
CELL DEATH ASSAY
Cells were seeded at a density of 500 per well in 96-well plates; cells
were then treated with increasing concentrations of CNTs (0.3–
30µg/mL) for 72 h. Supernatants and attached cells were collected
separately and analyzed for necrosis and apoptosis, respectively,
using commercially available ELISA kit per the manufacturers’
instructions (Cell Death Detection ELISAPLUS, Roche Applied
Science, Indianapolis, IN, USA). For the propidium iodide (PI)
incorporation assay, cells were incubated with PI for the remaining
20 min of the assay. Photos were taken using EVOS fl AMF-4306
AMG microscopes.
CELL PROLIFERATION ASSAY
Cells were seeded at a density of 1× 104 per well and grown for
24 h on 10 mm glass coverslips sitting in 24-well plates. CNTs (0.3,
1, and 3µg/mL) were added as appropriate. Cells were treated with
5-bromo-2′-deoxyuridine (BrdU) (50µM; Sigma-Aldrich) for the
remaining 2 h of the assay. Cells were fixed with 4% paraformalde-
hyde and non-specific binding was prevented by incubating cells
in 3% bovine serum albumin (BSA) and 0.1% Triton X-100 solu-
tion for 30 min at RT. Cells were incubated overnight at 4°C with
mouse monoclonal anti-BrdU (1:50; Molecular Probes, Eugene,
OR, USA), then washed with PBS, and incubated for 2 h at RT with
Alexa Fluor 594 donkey anti-mouse (1:200; Molecular Probes)
and Hoechst 33342 (2µg/mL) (Sigma-Aldrich). All images were
captured using EVOS fl AMF-4306 AMG microscopes.
TETRAZOLIUM DYE (MTT) ASSAY
Cells (2,000 or 500 cells per well for 72 h or 5 days MTT, respec-
tively) were seeded in 96-well plates. CNTs were added for 24 h,
and then exposed to NIR. MTT was performed for 72 h or 5 days
after the sequential treatment. MTT assay was conducted accord-
ing to the manufacturer’s protocol (EMD Chemical, Gibbstown,
NJ, USA).
COLONY-FORMING ASSAY
Glioma cells were seeded in 12-well slide chambers (IBIDI,Verona,
WI, USA) at 200 cells per well. Subsequently, cells were treated with
CNTs for 24 h and then exposed to NIR. At the end of 10 days,
colonies were visualized by staining with 1% methylene blue in
methanol for 1 h and quantified.
IN VIVO STUDIES
All animal protocols were approved by the Institutional Animal
Care and Use Committee of the University of Southern California.
Luciferase-labeled U251-TMZ-resistant glioma cells (5× 105 cells
in 50µL) were implanted subcutaneously. When tumors reached
12± 2 mm3, animals were imaged and randomly distributed into
groups of four each, CNT treatment was performed by injecting
intratumorally a total volume of 50µL. One day after the CNT
injection, a single NIR laser treatment (10 min at 6.75 W/cm2)
was performed at the tumor site. Tumor sizes were measured every
2 days and mice were imaged weekly. For the imaging, mice were
injected with 1 mg/kg Viviren™. In vivo Renilla Luciferase Sub-
strate (Promega, Madison, WI, USA) administered intravenously
and imaged using the IVIS 200 optical imaging system (Caliper
Life Sciences, Hopkinton, MA, USA); images were analyzed using
LIVING IMAGE software (Caliper Life Sciences).
STATISTICAL ANALYSIS
Statistical analysis was performed using GraphPad Prism 5.0
(GraphPad Software, San Diego, CA, USA). Statistical significance
was considered relevant for p values<0.05 using one-way analysis
of variance followed by Bonferroni or Dunnett post hoc test. Data
are presented as mean± standard error of the mean (SEM). Every
experimental condition was tested in three sets of independent
experiments unless stated otherwise, and performed in duplicates
or triplicates.
RESULTS
CNTs ARE NOT CYTOTOXIC TO GLIOMA CELLS BUT DECREASE CELL
PROLIFERATION
To determine whether exposure to CNTs alone induced cytotox-
icity, U251 glioma cells were incubated with different concentra-
tions of single-walled CNTs (0.3–30µg/mL). Both apoptotic and
necrotic cell death was evaluated 72 h after treatment using a cell
death ELISA kit. The results (Figure 1A) show that CNTs did
not induce either apoptosis or necrosis at concentrations equal
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FIGURE 1 | Effects of CNTs on cytotoxicity and proliferation of
glioblastoma cells. (A) U251 glioma cells were treated with different
doses of CNTs and evaluated after 72 h using the cell death ELISA. Doses
of CNTs <3µg/mL were not cytotoxic; apoptosis (left panel; p<0.05; n=3)
and necrosis (right panel; p< 0.05; n=3). (B) U251 glioma cells treated
with CNTs (0.3–3µg/mL) were evaluated for proliferation after 72 h using
Brdu incorporation assay; 3µg/mL significantly reduced cell proliferation
(n=3, *p<0.05).
to 3µg/mL; higher doses of CNT demonstrated both apoptotic
and necrotic cell death. Previous reports suggested that CNTs
interact with filamentous actin (F-actin) monomers, causing a
disruption of the cell cytoarchitecture and decreased proliferation
(13). Therefore, the effects of CNTs on cell proliferation were also
tested. Using the BrdU assay, the results demonstrated that CNTs,
at 3µg/mL, decreased cell proliferation by 20% as compared to
untreated control cells (Figure 1B). Based on these data, 3µg/mL
was selected for further studies on the cytotoxic effects of the
combination of CNTs and NIR.
NIR-EXPOSED CNTs INDUCE HYPERTHERMIA
We next investigated whether the highest non-cytotoxic dose of
CNTs (3µg/mL) was sufficient to significantly increase the tem-
perature upon NIR laser irradiation (6.75 W/cm2). The value
of 6.75 W/cm2 was selected since it was the highest power sup-
ported by the NIR laser used in this study, and therefore the most
efficient in inducing hyperthermia. The hyperthermia threshold
(40°C) was reached after 5 min of NIR irradiation in the presence
of 3µg/mL CNTs, while the untreated aqueous solution never
reached the lethal 40°C threshold, even after 15 min of exposure
to NIR. At 15 min, the temperature of the culture media alone
increased from 23 to 33.02± 0.02°C; by contrast in the presence
of CNTs (3µg/mL), the media significantly increased from 23 to
47.76± 0.06°C (Figure 2A).
CNTs ARE PREFERENTIALLY INTERNALIZED BY TUMOR CELLS
Since the internal concentration of CNTs may be critical to NIR
susceptibility, the internalization kinetics were evaluated using
fluorescently labeled CNTs. U251 glioma cells were treated with
fluorescently labeled CNTs (3µg/mL) and evaluated after 6, 24,
and 48 h of treatment (Figure 2B). Optimal internalization was
detected after 24 h; longer incubation time did not increase the
intracellular signal significantly. Control normal human astrocytes
were also tested for their ability to internalize CNTs. Unlike U251
cells, few astrocytes internalized CNTs (1 per 100 cells counted)
(Figure 2C), indicating that CNTs are selectively internalized, with
a preference for GBM cells as compared to normal astrocytes.
HYPERTHERMIA IS TOXIC TO GLIOMA CELLS
To evaluate the effects of hyperthermia on GBM, U251 cells were
incubated with 0.3, 1, and 3µg/mL of CNTs for 24 h, subse-
quently an NIR laser (6.75 W/cm2) was shone for a pulse of 5,
10, or 15 min (Figure 3A). Cell cultures were then evaluated after
72 h using the MTT assay. The results show that 10 min of NIR
with 3µg/mL produced the maximum decrease in cell viability
(13.38± 0.83%). To determine whether a second exposure would
enhance cell death, NIR treatment was repeated 24 h after the first
exposure (Figure 3B). Except for 15 min, which was also toxic
to untreated (no CNTs) cells, there was no significant difference
between one or two exposures to NIR. Hyperthermia-induced cell
death was dependent on both dose of CNTs and time of NIR
exposure (Figures 3A,B).
All subsequent experiments presented in this study used the
parameters of 24 h treatment of CNTs (3µg/mL) followed by a sin-
gle 10 min NIR exposure (6.75 W/cm2). This selection was based
on the fact that these settings have an NIR exposure that is safe for
untreated cells (99.69± 0.92% of control; Figure 3A), but induces
a higher cell death when combined with CNTs (13.38± 0.83% of
control; Figure 3A). Figure 3C depicts representative images of
U251 glioma cells 72 h after exposure to different treatments; sub-
sequently, cells were incubated with PI, which labels (red) necrotic
dead cells. Only in the presence of the combination of CNTs and
NIR did the number of PI-positive cells increase, with the majority
of PI-negative cells exhibiting a rounded morphology with mul-
tiple detached cells, indicative of cell stress. Although these cells
were not PI-positive, their metabolism was likely compromised.
We next tested the long-term effects of the combination
of CNTs and NIR exposure on a variety of cells using the
MTT assay for 7 days. Cell death was evaluated on the fol-
lowing cell cultures: U251 TMZ-sensitive cells (U251S), U251
TMZ-resistant (U251R), U87 glioma cells, U87 TMZ-resistant
(U87R), LN229 glioma cells, LN229 TMZ-resistant (LN229R),
T98G glioma cells, human BEC, human astrocytes, and primary
GSC isolated from three different human specimens (USC02,
USC04, and USC08) (Figure 4A). The results showed that photo-
induced hyperthermia is effective in killing different glioma cell
lines, including GSC (U251S: 8.34± 0.29%, U251R: 6.70± 1.18%,
U87: 7.70± 2.77%, U87R: 8.70± 2.02%, LN229: 8.53± 1.13%,
LN229R: 8.20± 2.15%, T98G: 6.86± 1.9%, USC02: 7.36± 3.13%,
USC04: 6.86± 1.47%, and USC08: 8.20± 0.52%). Cell toxicity
was achieved independently of TMZ-resistance status. By contrast,
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FIGURE 2 | Effects of sequential treatment of CNTs and NIR on
hyperthermia and CNT internalization by tumor cells. (A) U251 glioma
cells treated with CNTs (3µg/mL) and NIR (6.75W/cm2) demonstrated an
increase in temperature of the media compared to NIR alone
(***p<0.0001; n=3). Dashed line represents hyperthermia threshold
(40°C). (B) U251 glioma cells were incubated with fluorescein-labeled CNTs
(green); maximum internalization was observed after 24 h. (C) Astrocytes
were cultured with fluorescein-labeled CNTs for 24 h; few cells incorporated
CNTs. Total numbers of cells were identified by Hoechst nuclear staining
(blue). Scale bar is 20µm.
normal brain cells (BEC and astrocytes) exhibited no such cytotox-
icity compared to the tumor cell populations (BEC: 61.49± 2.95%,
astrocytes: 56.77± 10.57%). Thus, in vitro studies showed that
CNTs-induced hyperthermia is less cytotoxic to normal healthy
brain cells, as compared to tumor cells. Overall, tumor cell sur-
vival in vitro was decreased to levels below 10% throughout all
glioma-derived cell types that were tested (Figure 4A). We also
assessed the effects of this combination therapy on clonogenic
survival using the colony-forming assay (CFA), a long-term via-
bility assay (10 days) that measures the ability of tumor cells to
survive, proliferate, and form colonies. CNTs (3µg/mL) and NIR
laser alone (6.75 W/cm2; 10 min) had no statistically significant
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FIGURE 3 |The sequential treatment of CNTs and NIR induces lethal
hyperthermia. U251 glioma cells were treated with CNTs (0.3, 1, and
3µg/mL) and NIR once (A) or twice (B) for 5, 10, or 15 min; after 72 h, the
MTT cell viability assay showed that exposure to NIR (6.75W/cm2) reduced
cell survival (n=3, *p< 0.05, ***p<0.001 relative to 0 min of NIR of each
condition). (C) U251 glioma cells treated with CNTs (3µg/mL) and NIR (10 min
at 6.75W/cm2) for 72 h exhibit necrotic cell death as shown by propidium
iodide uptake (PI, red). Scale bar is 50µm.
FIGURE 4 | Effects of CNTs and NIR on several different glioma cells
compared to normal cells. (A) GBM cell types (U251S, U251R, U87, U87R,
LN229, LN229R, T98G), GBM cancer stem cells (USC02, USC04, USC08)
and normal cells (human BEC and astrocytes) were treated with CNTs
(3µg/mL) and a single NIR treatment (10 min at 6.75W/cm2). After 5 days,
cell viability was evaluated using the MTT assay. Normal cells demonstrated
greater viability compared to tumor cells (n=3, ***p<0.001). (B) U251
drug-sensitive and drug-resistant (U251R) cells were treated as described
above. After 10 days, the numbers of colonies were significantly reduced in
CNTs (3µg/mL) plus NIR (10 min at 6.75W/cm2) treated cells (n=3,
***p<0.001); (C) Representative images of the colonies are depicted.
effects on colony-forming ability (Figure 4B). However, the com-
bination of CNTs and NIR exposure caused a reduction in via-
bility to 0.926± 0.93% in U251S and to 0.762± 0.38% in U251R
(P < 0.0001).
THE SEQUENTIAL ADMINISTRATION OF CNTs AND NIR REDUCES
TUMOR GROWTH IN VIVO
We next investigated the effects of CNT-induced hyperthermia
in reducing tumor growth in vivo. Athymic nude mice were
implanted with U251R renilla luciferase-positive cells into the hind
flank. When tumors reached 12± 2 mm3, animals were distrib-
uted into five experimental groups: untreated, NIR alone (10 min,
6.75 W/cm2); CNTs alone (3µg/mL, 50µL injected intratu-
morally); CNTs (3µg/mL, 50µL injected intratumorally)+NIR;
CNTs (0.3µg/mL, 50µL injected intratumorally)+NIR. Twenty-
four hours after injection, tumors were exposed to NIR radiation
(10 min, 6.75 W/cm2). Tumor growth was monitored and animals
were euthanized when the tumor grew beyond 1.5 cm in diameter
or the animals showed signs of stress or discomfort. The con-
trol groups of untreated, NIR alone-, CNTs alone-treated animals
showed a similar tumor growth rate with no statistical differences
(Figure 5A). By contrast, a significant dose-dependent inhibi-
tion of tumor growth was obtained in animals treated with CNTs
plus NIR. The effectiveness of this therapy was dose-dependent
and more efficient at the highest concentration of CNTs tested
(3µg/mL), where a total elimination of the tumor was observed.
Furthermore, there were no signs of tumor recurrence up to
80 days after treatment (Figure 5B). Animals treated with a 10-fold
lower concentration of CNTs (0.3µg/mL) and NIR also exhibited
a significant inhibition of tumor growth, however, not as dramatic
as that observed with 3µg/mL CNTs in combination with NIR.
These data demonstrate that sequential administration of CNT
and NIR is effective in vivo and has clinical potential for patients
with recurrent, drug-resistant gliomas.
DISCUSSION
The mechanism of toxicity induced by CNTs is controversial and
may depend on different parameters such as nanotube type, size,
shape, presence of impurities, and route of administration (14).
The nanotubes used in our study were prepared by arc discharge
and presented a 1.4 nm mean diameter and 1µm mean length;
these CNTs were non-toxic when used in concentrations up to
3µg/mL. As previously reported by others, CNTs did significantly
decrease cell proliferation, but only at 3µg/mL. (13, 15).
Our data clearly show that CNTs, at non-cytotoxic concentra-
tions, generate heat when exposed to NIR in a time-dependent
fashion (Figure 2A). Notably, we detected a preferential uptake of
CNTs by glioma cells versus their healthy counterparts, astrocytes
(Figures 2B,C). GBM is a highly infiltrative tumor. Tumor cells
migrate deeper into surrounding normal healthy brain. This char-
acteristic makes the surgical resection a complicated task, leading
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FIGURE 5 |The sequential, combination therapy with CNTs and NIR
inhibits tumor growth in vivo. Athymic nude mice implanted with U251R
luciferase-positive cells were either left untreated or treated with NIR (10 min
at 6.75W/cm2) alone, CNTs alone (3µg/mL), CNTs (3µg/mL)+NIR, and CNTs
(0.3µg/mL)+NIR; four animals/group. (A)Tumor size was measured every
2 days; day 0 accounts for the day mice were treated and followed up. Control
groups (untreated, treated with CNTs alone, or treated with NIR alone) were
statistically identical. Only treatment with CNTs (3µg/mL)+NIR showed
tumor remission (n=4; *p<0.05, ***p<0.001 relative to untreated group).
(B) Representative images of mice at day 27 exhibited tumors. By contrast,
animals treated with CNTs (3µg/mL)+NIR group did not show any tumor
(n=4) even at the termination of the experiment (day 80).
either to an incomplete resection (and concomitant recurrence) or
an excessive resection (damaging eloquent brain regions). There-
fore, a therapy that could target specifically GBM cells would be
beneficial for the complete eradication of the tumor. Although
CNTs may seem an unlikely candidate, their specific uptake by
GBM cells demonstrated here, justify their therapeutic use. Dif-
ferences in CNT uptake may be explained by the mechanism of
internalization chosen by these cells. There are reports demon-
strating that CNTs enter cells through endocytosis (16, 17), specif-
ically via tip recognition through receptor binding (18). These
receptors may include scavenger receptors, lectin receptors, and
integrin receptors. Interestingly, up-regulated integrin signaling is
common for several invasive cancer types, including glioblastoma
(19), thus supporting our observations.
Single-walled CNTs induce hyperthermia by generating strong
optical absorptions in the NIR region while biological tissues are
fairly transparent to these wavelengths. NIR and CNT-induced
cell death was predominately necrotic (Figure 3C); hyperthermia
is known to induce necrosis (7). Recently, graphene nanoparticles
were shown to be more efficient in inducing lethal hyperther-
mia to U251 cells in vitro than CNTs (20). However, no uptake
studies were performed on these cells; it would be of particular
interest if the same preferential uptake observed by us was also
observed with graphene nanoparticles. The efficacy of CNTs and
NIR was reported for different types of cancer (6, 21–23). How-
ever, it is still unclear if this strategy can be used for glioblastoma.
Wang and colleagues studied the efficacy of CNTs conjugated with
CD133 antibody to target GBM cancer stem-like cells for pho-
tothermolysis (24). However, they did not compare the efficacy of
their conjugated CNTs with unconjugated ones. The CNTs used by
us were efficiently internalized by both GBM stem cells and tumor
cells without the need of conjugation. Moreover, the in vivo effect
reported by Wang et al. was obtained by pre-treating cells with
CNTs before grafting them, whereas we performed a therapeutic
approach. In our study, we only injected CNTs after confirm-
ing that the tumor was established. Furthermore, our treatment
was equally efficient on both therapy-resistant cells and GSC,
highlighting the clinical relevance of this therapy. We show here
that GBM-derived cells were more sensitive to hyperthermia than
normal BEC and astrocytes. These data are in accordance with pre-
vious studies, which showed that selective tumor killing is achieved
at temperatures between 40 and 44°C, while most normal tissues
remain undamaged at temperatures of up to 44°C for as long as
1 h (8).
As a proof of concept for clinical use, we performed in vivo
experiments using human TMZ-resistant glioma cells in the
xenograft subcutaneous rodent tumor model. Drug-resistant cells
were used because this is the most challenging malignant popula-
tion to treat. In this mouse model, CNTs were delivered intratu-
morally. The following day, the NIR laser exposure was initiated
(day 0 in Figure 5A). Similarly to the in vitro data, a maximum
uptake of CNTs was observed 24 h after administration (Sup-
plementary Figure 1). A single 10 min hyperthermia treatment
was sufficient for the observed dramatic reduction in tumor size
(Figures 5A,B). Animals pre-treated with CNTs and exposed to
NIR generated a small skin lesion, which disappeared within 24–
48 h, leaving no visible mark on the skin. The depth of the lesion
was related to the concentration of CNTs injected; this was a major
consideration in determining the final dose of CNTs. All animals
treated with this single sequential combination therapy at 3µg/mL
exhibited tumor shrinkage and ultimately no detectable tumor as
confirmed by bioluminescence imaging. Animals treated with a
10-fold lower CNT concentration (0.3µg/mL) showed a signifi-
cant tumor regression albeit not complete. These data are in accor-
dance with our in vitro results and other publications where the
effects of CNT and NIR treatment were concentration-dependent
(6, 11, 25).
From a clinical standpoint, the use of hyperthermia in brain
tumors has been called laser interstitial thermal energy. Two
companies, Monteris Medical (Plymouth, MN, USA) and Bio-
tex (Houston, TX, USA) have both developed sophisticated high
energy lasers for hyperthermia treatment. The problem with both
systems is that local energy is deposited to a focal area using
an introduced probe into the brain. As a result, each treatment
requires a new invasive procedure. The use of high energy lasers
also raises the risk of injury to normal cells in a non-targeted
fashion. We envision our CNT treatment, followed by NIR, to be
selective, less invasive, and potentially repeatable. Specificity can
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be obtained by local introduction of CNTs into the tumor cavity
after surgical resection. Non-invasive treatment can be obtained
by using external NIR-directed stereotactically into the tumor bed.
Lastly, repeatability is most likely possible, as long as CNTs remain
in the tumor bed, and are taken up by existing tumor cells after
the previously irradiated tumor cells die. In our anticipated clin-
ical application, we propose to deliver the CNTs locally rather
than perform a systemic delivery, thereby avoiding the challenges
of the blood–brain barrier (BBB). However, studies performed
by Yang and colleagues revealed that single-walled CNTs are able
to cross the BBB likely due to their nanostructure and partic-
ularly their nanoneedle-like shape. In their study, CNTs were
found to be internalized by brain cells by transmission electron
microscopy (26).
There are a number of potential problems with this therapy that
still need to be resolved. First, an in vivo orthotopic glioma model
must be explored to demonstrate the superiority of this approach
compared to “standard” hyperthermia. Second, the specificity of
CNTs for tumor cells versus normal cells over the long-term is
not known. CNTs left in the tumor cavity may migrate out to the
adjacent normal brain and induce undesirable by-stander effects
to the normal brain not envisioned at the time of treatment. How-
ever, the advantage of leaving CNTs in the tumor bed enables NIR
application on a repeated basis. Lastly, the effect of the skull in
NIR is not certain. Other studies have shown that NIR is capable
of penetrating the skull (27). This skull penetration by NIR would
be the ideal scenario. One alternative would be to leave the bone
flap off, and place it intra-abdominally.
In conclusion, the sequential combined therapy using CNTs
and then NIR is a powerful cancer therapy for the elimination
of malignant cells with minimal effects on normal tissues. Fur-
thermore, all GBM cells tested internalized CNTs and were sensi-
tive to hyperthermia, independent of their drug resistance status.
Our approach opens promising perspectives for the treatment of
therapy-resistant gliomas and possibly other cancer types.
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